Despite our findings that targeting ETV4 may potentiate anti-tumor immunity and improve responses to immune checkpoint blockade in melanoma, translating ETV4-targeted therapies into clinical practice presents a significant challenge. This evidence concerns the gene ETV4 and melanoma.